Company overview
BioSenic is a biotech company specializing in clinical-stage therapeutics for serious autoimmune and inflammatory diseases, as well as cell repair and bone regeneration. The company develops two primary platforms: an arsenic trioxide (ATO) platform targeting systemic autoimmune diseases including graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis; and an allogeneic mesenchymal stromal cell (ALLOB) platform for regenerative medicine and orthopedic applications. BioSenic operates as a publicly listed company on Euronext Brussels and Paris following its merger with Bone Therapeutics.
Biosenic is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include autoimmune disease therapeutics, arsenic trioxide platform, mesenchymal stromal cells, graft-versus-host disease, systemic lupus erythematosus.
Structured facts
- Website
- https://www.biosenic.com
- Markets served
- United States & Americas
- Keywords
- autoimmune disease therapeutics, arsenic trioxide platform, mesenchymal stromal cells, graft-versus-host disease, systemic lupus erythematosus
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Frequently asked questions
- What are BioSenic's primary therapeutic platforms?
- BioSenic operates two complementary platforms: the ATO (arsenic trioxide) platform for systemic autoimmune diseases, which leverages arsenic's immunomodulatory and anti-inflammatory properties; and the ALLOB allogeneic mesenchymal stromal cell platform for tissue repair and bone regeneration using immune-privileged cells sourced from healthy donors.
- What disease indications does BioSenic target?
- BioSenic's lead indications include graft-versus-host disease (GvHD), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and sepsis syndrome. The company is also developing applications in orthopedics and bone disorders, with ongoing clinical trials and patent filings to expand its therapeutic scope.
- What is the regulatory and clinical status of BioSenic's programs?
- BioSenic's arsenic trioxide platform has demonstrated safety and efficacy in clinical programs, with the company actively conducting Phase III trials. The underlying arsenic trioxide technology has FDA and EMA market approvals for acute promyelocytic leukemia, providing a validated mechanism of action for autoimmune applications.
- What is BioSenic's geographic presence and market access?
- BioSenic holds an exclusive worldwide license from CNRS to use arsenic in its therapeutic platform. The company is publicly listed on Euronext Brussels and Paris, indicating European regulatory compliance and access to capital markets for funding clinical development.
Related editorial coverage
- Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD
- NIKTIMVO (Axatilimab) Approved in Australia as First-in-Class Chronic Graft-Versus-Host Disease Treatment
- InnoCare Pharma Begins Phase III Trial of Orelabrutinib for Systemic Lupus Erythematosus Treatment
- AstraZeneca's SAPHNELO Autoinjector Approved by FDA for Self-Administration in Lupus Treatment
- FDA Accepts Genentech's Gazyva Application for Systemic Lupus Erythematosus Treatment
Explore lab tools and QA/QC resources for R&D teams.
